Summary
Effective 2027-01-01, UnitedHealthcare Community Plan of New Mexico Medicaid expanded its denosumab policy: Jubereq and Osvyrti are preferred products covered under the Diagnosis-Specific Criteria, while Boncresa, Oziltus, and Ponlimsi are non-preferred and covered only when the Preferred Product Criteria and Diagnosis-Specific Criteria are both met. The postmenopausal osteoporosis criteria add a very-high-fracture-risk pathway for initial therapy, and HCPCS codes Q5166, Q5171, and Q5173 were added.
Get alerts when payers change rules like this one
We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.